goserelin acetate extended-release microspheres LY01022

{
  "id": "MLC-T-ONC-014011",
  "term": "goserelin acetate extended-release microspheres LY01022",
  "field": "Oncology and biomedicine",
  "definition": "A long-acting, extended-release (ER) microsphere formulation of the acetate form of goserelin, a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH), with potential antineoplastic activity. Upon administration of goserelin acetate ER microspheres LY01022, goserelin is released over an extended period of time and binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of the goserelin ER formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. LY01022 prolongs the dosing cycle to a three-month period, thereby reducing the frequency of injections and potentially improving compliance.",
  "synonyms": [
    "goserelin acetate ER microspheres LY01022",
    "long-acting goserelin microspheres LY01022",
    "goserelin acetate sustained-release microspheres LY01022",
    "goserelin acetate SR microspheres LY01022"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/goserelin-acetate-extended-release-microspheres-ly01022/"
}